What to expect at Trump Jr.-backed ‘Steroid Olympics’ this Sunday
A new sports competition featuring Olympic medalists will take place in Las Vegas on Sunday. The twist? The…
Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with…
White House adds generic drugs to direct-to-consumer TrumpRx site
President Donald Trump speaks to introduce the TrumpRx website in the South Court Auditorium of the White House…
Hantavirus cases spark surge in pharma, biotech stocks — here’s why
ILLUSTRATION of hantavirus testing concept with laboratory tubes containing cotton swabs and HANTAVIRUS labels photographed in front of…
FDA withdrew studies finding Covid, shingles vaccines were safe
The FDA blocked the publication of several studies supporting the safety of vaccines against Covid and shingles in…
Apotex becomes the first Canadian‑based pharmaceutical company to receive Health Canada approval for a generic equivalent of Ozempic®
TORONTO, May 1, 2026 /PRNewswire/ – Apotex Inc. (“Apotex” or the “Company”), Canada’s largest Canadian‑based global health company,…
AstraZeneca stock falls after FDA panel votes against new cancer drug
Shares of AstraZeneca turned lower Friday after U.S. regulatory advisors voted against approving its experimental cancer drug. An…
Erasca touts strong early results in pancreatic and lung cancer therapy trial
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
Crispr gene editing treatment from Intellia succeeds in Phase 3 trial
Intellia Therapeutics, building exterior and company sign, Cambridge, Massachusetts, USA. Spencer Grant | Universal Images Group | Getty…
Regeneron inks drug pricing deal with Trump, will offer hearing-loss therapy for free
U.S. President Donald Trump (C) speaks during an event on advancing health care affordability in the Oval Office…
Eli Lilly’s $3.25B acquisition of Kelonia Therapeutics caps startup’s tortuous ride
Eli Lilly is spending $3.25 billion to acquire Kelonia Therapeutics, a small biotech company developing cell therapies for…
Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies
Kelonia’s lead program, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 for…